Earnings Scheduled For February 23, 2023
Companies Reporting Before The Bell
• ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter.
Oppenheimer Initiates Coverage On Relay Therapeutics with Outperform Rating, Announces Price Target of $33
Oppenheimer analyst Matthew Biegler initiates coverage on Relay Therapeutics (NASDAQ:RLAY) with a Outperform rating and announces Price Target of $33.
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday’s Mid-Day Session
Gainers
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial.
Relay Therapeutics Q3 EPS $(0.76) Misses $(0.71) Estimate, Sales $344.00K May Not Compare To $1.66M Estimate
Relay Therapeutics (NASDAQ:RLAY) reported quarterly losses of $(0.76) per share which missed the analyst consensus estimate of $(0.71) by 7.04 percent. This is a 15.15 percent decrease over losses of $(0.66) per share
Earnings Scheduled For November 3, 2022
Companies Reporting Before The Bell
• Hyatt Hotels (NYSE:H) is estimated to report quarterly earnings at $0.28 per share on revenue of $1.45 billion.
5 Analysts Have This to Say About Relay Therapeutics
Relay Therapeutics (NASDAQ:RLAY) has observed the following analyst ratings within the last quarter:
Wells Fargo Slashes Price Target On This Stock By Over 71%, Also Check Out Other Major PT Changes Here
Wells Fargo cut the price target on Cabaletta Bio, Inc. (NASDAQ: CABA) from $14 to $4. Wells Fargo analyst Derek Archila maintained the stock with an Overweight rating. Cabaletta Bio shares gained 0.9% to trade at $0.92 on Wednesday.
JMP Securities Maintains Market Outperform on Relay Therapeutics, Raises Price Target to $38
JMP Securities analyst Silvan Tuerkcan maintains Relay Therapeutics (NASDAQ:RLAY) with a Market Outperform and raises the price target from $35 to $38.
Tesla, Meta, NVIDIA And Other Big Losers From Tuesday
U.S. stocks closed sharply lower with the Nasdaq Composite dipping more than 5% on Tuesday. Here is the list of some big stocks moving lower in the previous session.
Why Comera Life Sciences Shares Jumped 101%; Here Are 74 Biggest Movers From Yesterday
Gainers
Akero Therapeutics, Inc. (NASDAQ: AKRO) shares jumped 136.8% to settle at $29.05 on Tuesday after the company's Phase 2b HARMONY study met its primary endpoint for both the 50mg and 28mg EFX dose groups.